Tarsus Pharmaceuticals’ (TARS) “Buy” Rating Reiterated at HC Wainwright

Tarsus Pharmaceuticals (NASDAQ:TARS)‘s stock had its “buy” rating reissued by equities research analysts at HC Wainwright in a research note issued to investors on Wednesday,Benzinga reports. They currently have a $73.00 price objective on the stock. HC Wainwright’s price objective points to a potential upside of 76.80% from the company’s previous close.

Other research analysts also recently issued reports about the company. Oppenheimer upped their price target on Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the company an “outperform” rating in a report on Wednesday, January 22nd. The Goldman Sachs Group upped their target price on shares of Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the company a “neutral” rating in a research note on Friday, November 15th. Guggenheim reiterated a “buy” rating on shares of Tarsus Pharmaceuticals in a research note on Monday. Finally, Barclays increased their price target on Tarsus Pharmaceuticals from $60.00 to $62.00 and gave the company an “overweight” rating in a report on Monday, January 27th. One analyst has rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $58.00.

Tarsus Pharmaceuticals Price Performance

TARS stock opened at $41.29 on Wednesday. The company has a debt-to-equity ratio of 0.30, a current ratio of 5.42 and a quick ratio of 5.38. Tarsus Pharmaceuticals has a 1 year low of $20.08 and a 1 year high of $57.28. The firm has a 50-day moving average of $51.51 and a 200 day moving average of $43.00. The company has a market cap of $1.58 billion, a P/E ratio of -10.84 and a beta of 1.01.

Tarsus Pharmaceuticals (NASDAQ:TARS) last issued its quarterly earnings results on Tuesday, February 25th. The company reported ($0.60) EPS for the quarter, topping analysts’ consensus estimates of ($0.68) by $0.08. Tarsus Pharmaceuticals had a negative return on equity of 55.86% and a negative net margin of 103.64%. The firm had revenue of $66.41 million for the quarter, compared to analysts’ expectations of $58.80 million. On average, sell-side analysts forecast that Tarsus Pharmaceuticals will post -3.17 EPS for the current year.

Hedge Funds Weigh In On Tarsus Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Crowley Wealth Management Inc. purchased a new position in shares of Tarsus Pharmaceuticals in the 4th quarter worth $25,000. GF Fund Management CO. LTD. bought a new stake in shares of Tarsus Pharmaceuticals in the 4th quarter valued at approximately $44,000. R Squared Ltd purchased a new position in shares of Tarsus Pharmaceuticals in the 4th quarter worth approximately $53,000. FMR LLC boosted its holdings in shares of Tarsus Pharmaceuticals by 236.6% in the 3rd quarter. FMR LLC now owns 5,032 shares of the company’s stock worth $166,000 after purchasing an additional 3,537 shares during the period. Finally, Quarry LP purchased a new stake in Tarsus Pharmaceuticals during the 4th quarter valued at $166,000. 90.01% of the stock is owned by institutional investors.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.